Ping An Biomedical shares surge 45.0% after-hours after receiving strategic investment from 58 Group, Amiba Capital, and Magcloud Group executives.

Ping An Biomedical surged 45.0% in after-hours trading following the announcement of a strategic investment from high-profile industry figures, including Yao Jinbo of 58 Group, Wang Donghui of Amiba Capital, and Li Daxue of Magcloud Group. The investors, known for their expertise in technology, capital operations, and industrial ecosystems, emphasized the company’s strong biopharmaceutical R&D capabilities and long-term growth potential. This development aligns with Ping An Bio’s “technology empowering healthcare” strategy, signaling robust institutional confidence in its innovation and commercialization prospects. The investment round further strengthens the company’s ability to integrate biopharmaceutical research, clinical translation, and industrial resources, positioning it for scalable global expansion.